Sector intelligence and perspective
April 26, 2018
As the relative strength index (RSI) is neither overbought nor oversold.
Yet the extended market indication of the IBB was +0.43% after closing -0.1% as the XBI (+0.17%) and IWM (+0.19%) are up
Pre-open indications: 2 BUY and 1 SELL
Financings: Sangamo Therapeutics (SGMO) prices 23.31 M offering at $16.25 to raise $200 M
Q1/18 financial results/earnings: MiMedx Group (MDXG)
Where the understanding of the indications sheds light on share pricing!
April 26, 2018
SGMO closed down -$0.50 after a -$0.35 decline and is down another -$0.95 (-5.49% in the pre-market
SGMO has 86.34 M shares outstanding with a float of 84.76 M shares
April 26, 2018
And a sigh of relief …
Next issue – which pricing is sustainable?
The NASDAQ (+1.64%), IBB (+1.98%) popped while volume was still low
Pre-open indications: 1 HIT and 2 MISS
End of day briefing; the “numbers” speak; if you know what happened today, you’ll understand what you need to do tomorrow!
April 23, 2018
PSTI closed Friday at $1.20 (-$0.04) and is UP +$0.04 in the pre-market The 5-year joint project was granted $2.5 million from the U.S. NIH
April 16, 2018
Closed down -$0.04 and is up +$0.0 or +7.28% to $1.09 ONVO continues to map out a range of relevant conditions for creating NASH, including all components of the disease (fat accumulation, inflammation and fibrosis).
April 12, 2018
ONVO closed down -$0.01 to $1.01 and is UP +$0.04 or +$0.04 or +3.96 These new data points provide strong support for the application of the NAFLD model to high-value drug profiling, including the possible creation of patient or population-specific model variants.
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
© 2018 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
